Rong Wang

Rong Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HZHuijuan Zhao
Huijuan Zhao
ZWZiqing Wei
Ziqing Wei
GSGuomin Shen
Guomin Shen
YCYixiang Chen
Yixiang Chen
XHXueqin Hao
Xueqin Hao
RWRong Wang
Rong Wang
Poly(rC)-binding proteins (PCBPs), a defined subfamily of RNA binding proteins, are characterized by their high affinity and sequence-specific interaction with poly-cytosine (poly-C). The PCBP family comprises five members, including hnRNP K and PCBP1-4. These proteins share a relatively similar structure motif, with triple hnRNP K homology (KH) domains responsible for recognizing and combining C-rich regions of mRNA and single- and double-stranded DNA. Numerous studies have indicated that PCBPs play a prominent role in hematopoietic cell growth, differentiation, and tumorigenesis at multiple levels of regulation. Herein, we summarized the currently available literature regarding the structural and functional divergence of various PCBP family members. Furthermore, we focused on their roles in normal hematopoiesis, particularly in erythropoiesis. More importantly, we also discussed and highlighted their involvement in carcinogenesis, including leukemia and lymphoma, aiming to clarify the pleiotropic roles and molecular mechanisms in the hematopoietic compartment.

26 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
RWRong Wang
Rong Wang
HZHuijuan Zhao
Huijuan Zhao
YLYang Liu
Yang Liu
BKBing Kang
Bing Kang
JCJun Cai
Jun Cai
Objective: Antinuclear antibodies (ANAs) have been reported to be associated with cancers. However, the role of different ANA patterns in cancers is poorly understood, especially in leukemia. This study aimed to investigate the association between ANA patterns and the outcome of leukemia in a retrospective cohort.Methods: A total of 429 adult patients initially diagnosed with leukemia at Henan Provincial People’s Hospital from January 2014 to December 2018 were included in this study, including information on patients without positive ANAs at the time of initial diagnosis, preexisting autoimmune diseases, infectious diseases, etc. The data were retrieved up to December 2020. The final sample included 196 adult patients. The risk of death outcome according to ANA patterns was estimated using multivariable Cox proportional hazards models and the overall survival for ANA patterns was analyzed using Kaplan–Meier curve.Results: ANAs with a nucleolar pattern versus negative ANA were associated with a two-fold increased risk of death outcome in leukemia, independent of sex, age, leukemia immunophenotype, cytogenetic abnormality, treatment, and blood transfusion. Further analysis revealed that the association was more significant in elder patients (≥60 years) and patients treated with tyrosine kinase inhibitor or chemotherapy (P for interaction = 0.042 and 0.010). Notably, the patients with a nucleolar pattern had shorter survival than the patients with a non-nucleolar pattern or without ANA (p < 0.001).Conclusion: ANAs with a nucleolar pattern are a significant predictor of poor prognosis, providing clues for prognostic assessment in patients with leukemia.

20 September 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
KJKeying Jing
Keying Jing
HZHuijuan Zhao
Huijuan Zhao
JCJun Cai
Jun Cai
LCLianlian Chen
Lianlian Chen
PZPeiming Zheng
Peiming Zheng
RWRong Wang
Rong Wang
Objective: Autoantibodies have been reported to be associated with cancers. As a biomarker, autoantibodies have been widely used in the early screening of lung cancer. However, the correlation between autoantibodies and the prognosis of lung cancer patients is poorly understood, especially in the Asian population. This retrospective study investigated the association between the presence of autoantibodies and outcomes in patients with lung cancer.Methods: A total of 264 patients diagnosed with lung cancer were tested for autoantibodies in Henan Provincial People’s Hospital from January 2017 to June 2022. The general clinical data of these patients were collected, and after screening out those who met the exclusion criteria, 151 patients were finally included in the study. The Cox proportional hazards model was used to analyze the effect of autoantibodies on the outcomes of patients with lung cancer. The Kaplan-Meier curve was used to analyze the relationship between autoantibodies and the overall survival of patients with lung cancer.Results: Compared to lung cancer patients without autoantibodies, those with autoantibodies had an associated reduced risk of death (HRs: 0.45, 95% CIs 0.27~0.77), independent of gender, age, smoking history, pathological type, and pathological stage of lung cancer. Additionally, the association was found to be more significant by subgroup analysis in male patients, younger patients, and patients with small cell lung cancer. Furthermore, lung cancer patients with autoantibodies had significantly longer survival time than those without autoantibodies.Conclusion: The presence of autoantibodies is an independent indicator of good prognosis in patients with lung cancer, providing a new biomarker for prognostic evaluation in patients with lung cancer.

22 May 2025 in Scientific Reports
Verified
Journal Article
Open access
YYYouhua Yuan
Youhua Yuan
JXJunhong Xu
Junhong Xu
GCGuohua Chen
Guohua Chen
YLYan Liu
Yan Liu
LOLibo Ouyang
Libo Ouyang
RWRong Wang
Rong Wang
The neutralisation ability of homologous and heterologous booster vaccinations against the KP.2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. Therefore, we aimed to evaluate the neutralisation of the Omicron variants by comparing serum samples from Chinese individuals who received heterologous boosters (from different manufacturers) with those who received homologous boosters (from the same manufacturer) against SARS-CoV-2. We collected serum samples from participants in the homologous (n = 38) and heterologous booster groups (n = 38) over 690 days. Serum pseudo virus neutralisation was tested against the prototype, XBB.1, JN.1, and KP.2 variants to detect neutralisation titres. An enzyme-linked immunosorbent assay was used to measure the total concentration of neutralising antibodies against the receptor binding domain of SARS-CoV-2. Neutralisation assays revealed 12.3-, 12.3-, and 11.4-fold reductions against JN.1, KP.2, and XBB.1 variants, respectively, compared with that against the prototype. However, no significant difference was observed in neutralising antibody titres among the JN.1, KP.2, and XBB.1 Omicron variants. Additionally, homologous boosters and men produced fewer neutralising antibodies compared to heterologous boosters and women. Thus, our results demonstrate that the Omicron variant KP.2 exhibits similar evasion properties to those observed in other variants.

14 February 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
HZHuijuan Zhao
Huijuan Zhao
ZWZiqing Wei
Ziqing Wei
GSGuomin Shen
Guomin Shen
YCYixiang Chen
Yixiang Chen
XHXueqin Hao
Xueqin Hao
RWRong Wang
Rong Wang
Corrigendum: Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy

1 November 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
KJKeying Jing
Keying Jing
LOLibo Ouyang
Libo Ouyang
JCJun Cai
Jun Cai
PZPeiming Zheng
Peiming Zheng
GLGang Li
Gang Li
RWRong Wang
Rong Wang
Purpose: There is a known association between tumor-associated autoantibodies (TAAbs) and lung cancer. TAAbs are currently used in clinical settings for the early detection of lung cancer. However, the relationship between TAAbs profiles and clinical outcomes in lung cancer patients remains incompletely understood. This study aims to investigate the association between TAAbs and survival rates in individuals diagnosed with lung adenocarcinoma. Patients and Methods: This study enrolled 161 patients diagnosed with lung adenocarcinoma at Henan Province People’s Hospital between January 2020 and December 2022. Levels of TAAbs were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Follow-up data were collected through December 2024. The association between TAAbs levels and disease progression was evaluated using Kaplan–Meier survival analysis and Cox proportional hazards models. Results: In the univariate analysis, the presence of p53 autoantibodies (anti-p53) and CAGE autoantibodies (anti-CAGE) was associated with an increased risk of reduced progression-free survival (PFS). In the multivariate analysis, anti-p53 remained significantly associated with shorter PFS, while anti-CAGE was not correlated with poor prognosis. The significant association between anti-p53 and worse PFS persisted after adjusting for gender, age, smoking status, pathological stage, and treatment. Kaplan–Meier survival analysis further confirmed that patients positive for anti-p53 had significantly shorter PFS (P = 0.0025). Conclusion: Tumor-associated autoantibody anti-p53 correlates poor prognosis in lung adenocarcinoma patients, offering novel insights into tumor prognosis.